Fri, May 31, 2019
Thu, May 30, 2019
Wed, May 29, 2019
Tue, May 28, 2019
Fri, May 24, 2019
Thu, May 23, 2019
Wed, May 22, 2019
Tue, May 21, 2019
Mon, May 20, 2019
Fri, May 17, 2019
Thu, May 16, 2019
Wed, May 15, 2019
Tue, May 14, 2019
Mon, May 13, 2019
Fri, May 10, 2019
Thu, May 9, 2019
Wed, May 8, 2019
Tue, May 7, 2019
Mon, May 6, 2019
Fri, May 3, 2019
Thu, May 2, 2019
Wed, May 1, 2019

Matthew Harrison Maintained (SRPT) at Buy with Decreased Target to $165 on, May 14th, 2019


  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. th-decreased-target-to-165-on-may-14th-2019.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Decreased Target from $169 to $165 on, May 14th, 2019.

Matthew has made no other calls on SRPT in the last 4 months.



There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Matthew


  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $188 on, Thursday, May 9th, 2019
  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Increased Target to $201 on, Friday, March 1st, 2019
  • Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $231 on, Thursday, February 28th, 2019
  • Christopher Marai of "Nomura" Maintained at Strong Buy with Increased Target to $230 on, Thursday, February 28th, 2019

Publication Contributing Sources